ER study sheds light on hidden xylazine in opioid overdoses

NCT ID NCT06949605

Completed Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study measured the amount of xylazine—a dangerous animal sedative often mixed with opioids—in the blood and urine of 75 emergency room patients who had a non-fatal opioid overdose. The goal was to see how common xylazine is and how well test strips can detect it. The findings could help emergency doctors better identify and respond to this growing threat.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors quickly detect xylazine in opioid overdoses and guide better emergency treatment.
What could go wrong: This was a small, observational study that only measured levels—it did not test any treatment or prove that detection improves outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID OVERDOSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute opioid poisoning Opiate Overdose substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID OVERDOSE SUBSTANCE USE DISORDERS

Contacts and locations

Locations

Icahn School of Medicine

New York, New York, 10029, United States
NYC Health + Hospitals/Elmhurst

Elmhurst, New York, 11373, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.